JP2016128399A5 - - Google Patents

Download PDF

Info

Publication number
JP2016128399A5
JP2016128399A5 JP2015118495A JP2015118495A JP2016128399A5 JP 2016128399 A5 JP2016128399 A5 JP 2016128399A5 JP 2015118495 A JP2015118495 A JP 2015118495A JP 2015118495 A JP2015118495 A JP 2015118495A JP 2016128399 A5 JP2016128399 A5 JP 2016128399A5
Authority
JP
Japan
Prior art keywords
amino
lipophilic
amino acids
group
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015118495A
Other languages
English (en)
Japanese (ja)
Other versions
JP6767096B2 (ja
JP2016128399A (ja
Filing date
Publication date
Priority claimed from GBGB1506127.8A external-priority patent/GB201506127D0/en
Application filed filed Critical
Priority to PL15793746T priority Critical patent/PL3230318T3/pl
Priority to US15/534,800 priority patent/US11083774B2/en
Priority to PCT/EP2015/075722 priority patent/WO2016091487A1/en
Priority to PT157937467T priority patent/PT3230318T/pt
Priority to DK15793746.7T priority patent/DK3230318T3/da
Priority to AU2015359881A priority patent/AU2015359881B2/en
Priority to EP15793746.7A priority patent/EP3230318B1/en
Priority to ES15793746T priority patent/ES2819282T3/es
Priority to LTEP15793746.7T priority patent/LT3230318T/lt
Priority to HUE15793746A priority patent/HUE051268T2/hu
Publication of JP2016128399A publication Critical patent/JP2016128399A/ja
Publication of JP2016128399A5 publication Critical patent/JP2016128399A5/ja
Priority to AU2019203199A priority patent/AU2019203199B2/en
Publication of JP6767096B2 publication Critical patent/JP6767096B2/ja
Application granted granted Critical
Priority to AU2021204356A priority patent/AU2021204356B2/en
Priority to US17/366,463 priority patent/US20230201305A9/en
Priority to US18/598,719 priority patent/US12239686B2/en
Priority to US19/022,157 priority patent/US20250332217A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015118495A 2014-12-11 2015-06-11 免疫チェックポイント阻害剤の組み合わせ Active JP6767096B2 (ja)

Priority Applications (15)

Application Number Priority Date Filing Date Title
ES15793746T ES2819282T3 (es) 2014-12-11 2015-11-04 Combinaciones de inhibidores de puntos de control inmunitarios
HUE15793746A HUE051268T2 (hu) 2014-12-11 2015-11-04 Immunellenõrzõpont-gátló kombinációk
US15/534,800 US11083774B2 (en) 2014-12-11 2015-11-04 Immune checkpoint inhibitor combinations
PCT/EP2015/075722 WO2016091487A1 (en) 2014-12-11 2015-11-04 Immune checkpoint inhibitor combinations
PT157937467T PT3230318T (pt) 2014-12-11 2015-11-04 Combinações de inibidores de pontos de controlo imunitários
DK15793746.7T DK3230318T3 (da) 2014-12-11 2015-11-04 Immune checkpoint-inhibitor-kombinationer
AU2015359881A AU2015359881B2 (en) 2014-12-11 2015-11-04 Immune checkpoint inhibitor combinations
EP15793746.7A EP3230318B1 (en) 2014-12-11 2015-11-04 Immune checkpoint inhibitor combinations
PL15793746T PL3230318T3 (pl) 2014-12-11 2015-11-04 Kombinacje inhibitora immunologicznego punktu kontrolnego
LTEP15793746.7T LT3230318T (lt) 2014-12-11 2015-11-04 Imuninės kontrolės taško inhibitorių kombinacijos
AU2019203199A AU2019203199B2 (en) 2014-12-11 2019-05-07 Immune checkpoint inhibitor combinations
AU2021204356A AU2021204356B2 (en) 2014-12-11 2021-06-25 Immune checkpoint inhibitor combinations
US17/366,463 US20230201305A9 (en) 2014-12-11 2021-07-02 Immune checkpoint inhibitor combinations
US18/598,719 US12239686B2 (en) 2014-12-11 2024-03-07 Immune checkpoint inhibitor combinations
US19/022,157 US20250332217A1 (en) 2014-12-11 2025-01-15 Immune checkpoint inhibitor combinations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB201422084 2014-12-11
GB1422084.2 2014-12-11
GBGB1506127.8A GB201506127D0 (en) 2015-04-10 2015-04-10 Immune checkpoint inhibitor combinations
GB1506127.8 2015-04-10

Publications (3)

Publication Number Publication Date
JP2016128399A JP2016128399A (ja) 2016-07-14
JP2016128399A5 true JP2016128399A5 (cg-RX-API-DMAC7.html) 2018-05-10
JP6767096B2 JP6767096B2 (ja) 2020-10-14

Family

ID=56384106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015118495A Active JP6767096B2 (ja) 2014-12-11 2015-06-11 免疫チェックポイント阻害剤の組み合わせ

Country Status (11)

Country Link
US (4) US11083774B2 (cg-RX-API-DMAC7.html)
EP (1) EP3230318B1 (cg-RX-API-DMAC7.html)
JP (1) JP6767096B2 (cg-RX-API-DMAC7.html)
AU (3) AU2015359881B2 (cg-RX-API-DMAC7.html)
DK (1) DK3230318T3 (cg-RX-API-DMAC7.html)
ES (1) ES2819282T3 (cg-RX-API-DMAC7.html)
HU (1) HUE051268T2 (cg-RX-API-DMAC7.html)
LT (1) LT3230318T (cg-RX-API-DMAC7.html)
PL (1) PL3230318T3 (cg-RX-API-DMAC7.html)
PT (1) PT3230318T (cg-RX-API-DMAC7.html)
WO (1) WO2016091487A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6767096B2 (ja) * 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
JP6810877B2 (ja) * 2016-12-26 2021-01-13 国立大学法人神戸大学 経口腫瘍ワクチンと免疫抑制阻害剤との併用によるがん治療
WO2018188761A1 (en) * 2017-04-13 2018-10-18 Lytix Biopharma As Method of reducing population size of tregs and/or mdscs
US11759485B2 (en) 2018-06-14 2023-09-19 Meiji Co., Ltd. Composition for enhancing immune checkpoint blockade therapy
CN114072135A (zh) 2019-06-20 2022-02-18 凯莫森特里克斯股份有限公司 治疗pd-l1疾病的化合物
CN110317245B (zh) * 2019-08-02 2021-04-09 郑州大学 Lag-3蛋白亲和环肽及其应用
CN114585359B (zh) 2019-10-16 2025-08-12 凯莫森特里克斯股份有限公司 用于治疗pd-l1疾病的杂芳基联苯酰胺
US11866429B2 (en) 2019-10-16 2024-01-09 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
WO2021142088A1 (en) * 2020-01-07 2021-07-15 The Trustees Of The University Of Pennsylvania Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies
EP4637800A1 (en) 2022-12-20 2025-10-29 Lytix Biopharma AS Compositions comprising an oncolytic peptide and chitosan
JP2025541902A (ja) 2022-12-20 2025-12-23 リティックス バイオファーマ エイエス ペプチドの水性製剤を含む医療用製品
CN117402828A (zh) * 2023-04-13 2024-01-16 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种人肺癌脑转移瘤细胞系及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EP1082134B1 (en) 1998-05-04 2008-07-16 Thomas Jefferson University Use of haptenised tumour cells and extracts thereof
GB0605685D0 (en) * 2006-03-21 2006-05-03 Lytix Biopharma As Inhibition of tumour growth
ES2350687T3 (es) * 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
GB0821616D0 (en) * 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
AU2010303149B2 (en) * 2009-09-30 2016-08-04 Board Of Regents, The University Of Texas System Combination immunotherapy for the treatment of cancer
US9410206B2 (en) * 2011-11-30 2016-08-09 John Wayne Cancer Institute Long noncoding RNA (lncRNA) as a biomarker and therapeutic marker in cancer
US10202454B2 (en) * 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
AU2015218633A1 (en) * 2014-02-21 2016-09-01 Abbvie Stemcentrx Llc Anti-DLL3 antibodies and drug conjugates for use in melanoma
CA2968406A1 (en) * 2014-12-09 2016-06-16 Mark D. Ayers System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
JP6813258B2 (ja) * 2014-12-11 2021-01-13 リティックス バイオファーマ エイエス 化学療法の組み合わせ
JP6767096B2 (ja) * 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ

Similar Documents

Publication Publication Date Title
JP2016128399A5 (cg-RX-API-DMAC7.html)
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
JP2018501197A5 (cg-RX-API-DMAC7.html)
MX2024004332A (es) Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos.
MX2018001193A (es) Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos.
JP2015504871A5 (cg-RX-API-DMAC7.html)
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
JP2018530554A5 (cg-RX-API-DMAC7.html)
JP2016527286A5 (cg-RX-API-DMAC7.html)
JP2016539096A5 (cg-RX-API-DMAC7.html)
JP2018522045A5 (cg-RX-API-DMAC7.html)
CY1118947T1 (el) Ασυμμετρες ουριες και ιατρικες χρησεις αυτων
AU2021203564B2 (en) Compositions comprising naphthyridine derivatives and aluminium adjuvant for use in treating solid tumors
JP2017508744A5 (cg-RX-API-DMAC7.html)
BR112018001534A2 (pt) inibidor de isocitrato desidrogenase idh1 r132h mutante
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
EA202090959A1 (ru) Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
RU2011123700A (ru) Нонапептид с противоопухолевой активностью
JP2018519324A5 (cg-RX-API-DMAC7.html)
JP2024133495A (ja) 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール
CY1120852T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας
FI3463436T3 (fi) Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää
EP3209328B1 (en) Inhibitors of lactate transporters for use in the treatment of inflammatory diseases
EA201101305A1 (ru) Лечение рака поджелудочной железы